Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions—A systematic review. Issue 2 (9th November 2017)

• Record Type: Journal Article
• Authors: Morano, William F.; Khalili, Marian; Chi, Dennis S.; Bowne, Wilbur B.; Esquivel, Jesus
• Is Part Of: Journal of surgical oncology. Volume 117:Issue 2(2018)
• Page Start: 245
• Page End: 259
• Publication Date: 2017-11-09
• Subjects: clinical trials -- cytoreductive surgery -- HIPEC -- peritoneal carcinomatosis -- peritoneal metastasis; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.24813
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract : Background: The field of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has suffered from a lack of clinical trials to validate its expanding use. Objective: To evaluate published and ongoing clinical trials seeking to better define role of CRS/HIPEC in the treatment of peritoneal surface malignancies. Methods: Systematic review by PubMed search was performed using terms "Clinical trial, " "intraperitoneal chemotherapy, " and "HIPEC."ClinicalTrials.gov and EudraCT registries were searched for active clinical trials. Eligibility included CRS/HIPEC trials investigating adult patient populations from published clinical reports and/or trials currently accruing or at completion. Results: Thirteen published trials and 57 active clinical trials were included for review. Conclusions: Published and ongoing U.S. and international clinical trials for CRS and HIPEC are defining important parameters that include improving patient selection, strategic sequences of treatment, cytoreductive strategies, chemotherapeutics, optimal hyperthermic temperature and timing, and toxicity profiles. Main barriers or limitations to trial development remain patient enrollment, trial design, and oncologic community collaboration. Overall progress is positive with increasing number of clinical trials throughout the world. Collaboration between surgeons and the wider oncologic community will be crucial to validate this important treatment strategy.